Consulta Rápida - Psicofármacos - 1Ed.pdf

PIPOTIAZINA
MEDICAMENTOS: INFORMAÇÕES BÁSICAS
do, pois pode ocorrer hipoglicemia durante
jejum prolongado e alguns dos seus sintomas
(taquicardia, tremor) mascarados. Os pacientes
podem ser treinados a reconhecer a sudorese
como principal sintoma de hipoglicemia
durante tratamento com β-bloqueador.
6. Os pacientes devem ter cuidado na condução
de veículos ou na operação de máquinas, pois
pode ocorrer tontura ou fadiga durante o início
do tratamento.
7. Em casos de grave comprometimento da função
renal ou hepática, pode ser necessária
redução da dose.
8. Atenção para a possibilidade de desenvolvimento
de quadro de hipomania quando da
associação entre o pindolol e um ISRS.
REFERÊNCIAS BIBLIOGRÁFICAS
1. Buitelaar JK, van der Gaag RJ, Swaab-Barneveld H, Kuiper
M.Pindolol and methylphenidate in children with attentiondeficit
hyperactivity disorder. Clinical efficacy and sideeffects.
J Child Psychol Psychiatry 1996; 37 (5): 587-95.
2. Perez V, Puiigdemont D, Gilaberte I, Alvarez E, Artigas F;
Grup de Recerca en Trastorns Afectius.Augmentation of
fluoxetine’s antidepressant action by pindolol: analysis of
clinical, pharmacokinetic, and methodologic factors. J Clin
Psychopharmacol 2001; 21 (1): 36-45.
3. Zanardi R, Artigas F, Franchini L, Sforzini L, Gasperini M,
Smeraldi E, Perez J.How long should pindolol be associated
with paroxetine to improve the antidepressant response? J
Clin Psychopharmacol 1997; 17 (6): 446-50.
4. Bordet R, Thomas P, Dupuis B.Effect of pindolol on onset
of action of paroxetine in the treatment of major depression:
intermediate analysis of a double-blind, placebo-controlled
trial. Reseau de Recherche et d’Experimentation Psychopharmacologique.
Am J Psychiatry 1998; 155 (10): 1346-51.
5. Maes M, Libbrecht I, van Hunsel F, Campens D, Meltzer
HY.Pindolol and mianserin augment the antidepressant
activity of fluoxetine in hospitalized major depressed patients,
including those with treatment resistance. J Clin Psychopharmacol
1999; 19 (2): 177-82.
6. Perez V, Soler J, Puigdemont D, Alvarez E, Artigas F.A
double-blind, randomized, placebo-controlled trial of
pindolol augmentation in depressive patients resistant to
serotonin reuptake inhibitors. Grup de Recerca en Trastorns
Afectius. Arch Gen Psychiatry 1999; 56 (4): 375-9.
7. Moreno FA, Gelenberg AJ, Bachar K, Delgado PL. Pindolol
augmentation of treatment-resistant depressed patients. J
Clin Psychiatry 1997; 58 (10): 437-9.
8. Berman RM, Darnell AM, Miller HL, Anand A, Charney
DS.Effect of pindolol in hastening response to fluoxetine in
the treatment of major depression: a double-blind, placebocontrolled
trial. Am J Psychiatry. 1997; 154 (1): 37-43.
9. Berman RM, Anand A, Cappiello A, Miller HL, Hu XS, Oren
DA, Charney DS.The use of pindolol with fluoxetine in the
treatment of major depression: final results from a doubleblind,
placebo-controlled trial. Biol Psychiatry. 1999; 45 (9):
1170-7.
10. Shiah IS, Yatham LN, Srisurapanont M, Lam RW, Tam
EM, Zis AP.Does the addition of pindolol accelerate the
response to electroconvulsive therapy in patients with major
depression? A double-blind, placebo-controlled pilot
study. J Clin Psychopharmacol 2000; 20 (3): 373-8.
11. Stein MB, Sareen J, Hami S, Chao J.Pindolol potentiation
of paroxetine for generalized social phobia: a double-blind,
placebo-controlled, crossover study. Am J Psychiatry 2001;
158 (10): 1725-7.
12. Dannon PN, Sasson Y, Hirschmann S, Iancu I, Grunhaus
LJ, Zohar J. Pindolol augmentation in treatment-resistant
obsessive compulsive disorder: a double-blind placebo controlled
trial. Eur Neuropsychopharmacol 2000; 10 (3): 165-
9.
13. Greendyke RM, Kanter DR.Therapeutic effects of pindolol
on behavioral disturbances associated with organic brain
disease: a double-blind study. J Clin Psychiatry 1986; 47 (8):
423-6.
14. Caspi N, Modai I, Barak P, Waisbourd A, Zbarsky H,
Hirschmann S, Ritsner M.Pindolol augmentation in
aggressive schizophrenic patients: a double-blind crossover
randomized study. Int Clin Psychopharmacol 2001; 16 (2):
111-5.
15. Szecsi E, Kohlschutter S, Schiess W, Lang E.Abrupt
withdrawal of pindolol or metoprolol after chronic therapy.
Br J Clin Pharmacol 1982; 13 (Suppl 2): 353S-357S.
16. Romero L, Bel N, Artigas F e cols. Effect os pindolol on
the function of pre- and postsynaptic 5-HT1A receptors: in
vivo microdialysis and electrophysiological studies in the rat
brain. Neuropsychopharmacology 1996; 15: 349-360.
PIPOTIAZINA
PIPORTIL (Lab. Aventis-Pharma)
• Embalagens com 20 comprimidos de 10 mg.
PIPORTIL L4 (Lab. Aventis-Pharma)
• Embalagens com 1 ampola de 4 mL ou 3 ampolas
de 1 mL. Cada mL contém 25 mg de éster
palmítico de pipotiazina.
FARMACOCINÉTICA
E MODO DE USAR
É um antipsicótico potente do grupo das fenotiazinas
piperazínicas. Como os demais fármacos do
grupo, é bem-absorvida por via oral, com alta taxa
de ligação protéica (90%). É metabolizada em nível
hepático e excretada pelo rim.
A pipotiazina tem sido utilizada no tratamento
dos sintomas psicóticos de diversos transtornos
como a esquizofrenia, psicoses breves, mania aguda,
transtorno esquizoafetivo, transtorno delirante,
depressão grave, agitação em pacientes com
234